Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 12/20 | 0.49 |
| ▸ | MEN1 | O00255 | 8/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.49 |
| ▸ | POLB | P06746 | 3/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 6/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.45 |
| ▸ | LMNA | P02545 | 5/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.44 |
| ▸ | PIKFYVE | Q9Y2I7 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | CASP3 | P42574 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL429532 | 1.00 | MAPT (0.49) | MAPTMEN1KMT2APOLBL3MBTL1 | |
| SCHEMBL10195987 | 1.00 | MAPT (0.49) | MAPTMEN1KMT2APOLBL3MBTL1 | |
| SCHEMBL12706252 | 0.93 | MAPT (0.46) | MAPTMEN1KMT2APOLBL3MBTL1 | |
| SCHEMBL13758948 | 0.90 | MAPT (0.62) | MAPTMEN1KMT2APOLBL3MBTL1 | |
| SCHEMBL426664 | 0.89 | MAPT (0.59) | MAPTMEN1KMT2APOLBL3MBTL1 | |
| SCHEMBL426665 | 0.89 | MAPT (0.59) | MAPTMEN1KMT2APOLBL3MBTL1 | |
| SCHEMBL10198698 | 0.89 | MAPT (0.59) | MAPTMEN1KMT2APOLBL3MBTL1 | |
| SCHEMBL10196628 | 0.83 | MAPT (0.57) | MAPTMEN1KMT2APOLBL3MBTL1 | |
| SCHEMBL13801461 | 0.82 | MAPT (0.56) | MAPTMEN1KMT2APOLBL3MBTL1 | |
| SCHEMBL14530242 | 0.81 | GAA (0.48) | MAPTMEN1KMT2APOLBL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7919487-B2 | Heteroaryl compounds | SYNTA PHARMACEUTICALS CORPORATION (US) | 2011-04-05 | — | — | US | claimed |
| WO-2006053109-A1 | HETEROARYL COMPOUNDS | SYNTA PHARMACEUTICALS CORP. (US) | 2006-05-18 | — | — | WO | claimed |
| US-20150174132-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | SYNTA PHARMACEUTICALS CORP (US) | 2015-06-25 | — | — | US | disclosed |
| US-20120021434-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | SYNTA PHARMACEUTICALS CORP. (US) | 2012-01-26 | — | — | US | disclosed |
| US-7919487-B2 | Heteroaryl compounds | SYNTA PHARMACEUTICALS CORPORATION (US) | 2011-04-05 | — | — | US | disclosed |
| US-20090163708-A1 | PROCESS FOR PREPARING MESYLATE SALTS OF IL-12 INHIBITORY COMPOUNDS | SYNTA PHARMACEUTICALS CORP. (US) | 2009-06-25 | — | — | US | disclosed |
| US-20070032493-A1 | Method for treating B cell regulated autoimmune disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2007-02-08 | — | — | US | disclosed |
| US-20060122156-A1 | Heteroaryl compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2006-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150174132-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | REL, NFATC1, BCL6 | MAPT 4316/4885MEN1 3751/4885KMT2A 1509/4885 |
| US-20060122156-A1 | Heteroaryl compounds | IL2, CCL11, IL4 | MAPT 2813/4885MEN1 3198/4885KMT2A 3739/4885 |
| US-20090163708-A1 | PROCESS FOR PREPARING MESYLATE SALTS OF IL-12 INHIBITORY COMPOUNDS | IL17A, IL23R, IL2 | MAPT 2815/4885MEN1 293/4885KMT2A 1939/4885 |
| US-20070032493-A1 | Method for treating B cell regulated autoimmune disorders | REL, NFATC1, BCL6 | MAPT 4316/4885MEN1 3751/4885KMT2A 1509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.